Updated:
Merck & Co.
Robert M. Davis chairs Merck & Co., the $280B pharmaceutical giant that turned Keytruda into a $25B-a-year oncology franchise.
Merck & Co.
Merck was founded in 1891 as the US subsidiary of the German Merck KGaA, operating independently until government seizure during World War I. It re-emerged as a standalone American corporation and went public in the 1940s, building one of the industry's longest-running dividend records. The modern firm took shape after the 2009 acquisition of Schering-Plough, which brought Keytruda's predecessor compound into Merck's pipeline. The company allocates capital across three main segments: human health pharmaceuticals, animal health, and a select set of collaborations with biotech partners. Human health operates primarily through direct research and development, co-promotion agreements, and licensing deals. Key positions include Keytruda in immuno-oncology, the Gardasil franchise in vaccines, and Januvia for diabetes. Merck Animal Health maintains a global footprint, selling products in more than 50 countries. The company co-invests alongside drug developers through its venture arm, the MRL Ventures Fund, and has completed partnerships with AstraZeneca on Lynparza and with Daiichi Sankyo on antibody-drug conjugates. Merck employs approximately 70,000 people and operates major research hubs in Rahway, New Jersey, West Point, Pennsylvania, and international sites including a large R&D center in London. The firm spun off its women's health and legacy products division as Organon in June 2021 in a transaction worth roughly $9B. In September 2023, Merck and Daiichi Sankyo jointly filed for FDA approval of patritumab deruxtecan for patients with previously treated EGFR-mutated non-small cell lung cancer (per Merck's official communications, September 2023). Merck's structure differs from its large-cap pharma peers in one notable way: the founding family, represented by the US-based Merck Family Fund, still holds a voice, a rare multi-generational link in an industry dominated by institutional ownership. This governance layer coexists with a board chaired by Davis, creating a dual stewardship model that spans the legacy of the original Merck name and the demands of a modern publicly traded drug developer.
General information
Firm type
other
Year founded
1891
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Kenilworth
Corporate office
Kenilworth, NJ, United States
Principals
Robert M. Davis
Chairman and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Merck?
Robert M. Davis, Chairman and CEO, sets the overall corporate capital allocation strategy. Davis oversees Merck's internal portfolio review process alongside the board's finance committee, with business development led by the chief strategy officer and the MRL Ventures team. External co-investment decisions, including the Daiichi Sankyo antibody-drug conjugate partnerships, require full board and management committee approval given the size of those commitments.
How does Merck source its pipeline investments?
Merck sources compounds through a combination of internal R&D, academic collaborations, and targeted acquisitions of biotech assets. The firm's venture arm, MRL Ventures Fund, scouts early-stage opportunities across oncology, vaccines, and infectious disease. Late-stage co-development partnerships, such as the $5.5B upfront deal with Daiichi Sankyo for three antibody-drug conjugates in October 2023, represent the firm's preferred model for bringing external assets into the portfolio without full M&A integration risk.
What is Merck's posture on co-investments alongside other pharmaceutical companies?
Merck regularly enters co-development and co-commercialization agreements with other pharma companies. The alliance with AstraZeneca on ovarian and breast cancer drug Lynparza shares profits and costs globally. The Daiichi Sankyo deal structure exemplifies the current model: Merck pays a large upfront sum plus contingent milestones in exchange for joint development rights and exclusive commercialization outside of Japan, while Daiichi Sankyo retains sole rights in its home market.
How does Merck's animal health business fit into the overall portfolio?
Merck Animal Health operates as a fully integrated division with its own R&D, manufacturing, and commercial organizations. The unit sells veterinary pharmaceuticals and vaccines in more than 50 countries. Unlike the human health segment, which is highly concentrated in oncology, animal health provides a diversified, lower-risk revenue stream with different patent-expiry dynamics.
What happens to Merck's business when Keytruda's patents expire?
Keytruda's key composition of matter patents begin expiring in 2028, and Merck has publicly acknowledged the looming revenue gap. The response strategy centers on three levers: advancing Keytruda into earlier-stage cancer treatment settings to lock in long-term patient relationships before generic entry, developing a subcutaneous formulation that may earn separate patent protection, and accelerating the pipeline of newly acquired assets, including the Daiichi Sankyo conjugates and the $11.5B acquisition of Acceleron Pharma in 2021.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: